The enigma of ectopic expression of FGFR3 in multiple myeloma: A critical initiating event or just a target for mutational activation during tumor progression

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The t(4;14)(pl 6.3;q32) translocation that occurs uniquely in a subset of multiple myeloma tumors results in ectopic expression of wild-type FGFR3 and enhanced expression of MMSET, a gene that is homologous to the MLL gene that is involved in acute myeloid leukemias. Wild-type FGFR3 appears to be weakly transforming in a hematopoietic murine model, whereas FGFR3 that contains kinase-activating mutations is strongly transforming in NIH3T3 cells and the hematopoietic model. The subsequent acquisition of FGFR3 kinase-activating mutations in some tumors with t(4;14) translocations confirms a role for FGFR3 in tumor progression. However, it remains to be proven if and how dysregulation of FGFR3 or MMSET mediates an early oncogenic process in multiplemyeloma.

Original languageEnglish (US)
Pages (from-to)288-293
Number of pages6
JournalCurrent Opinion in Hematology
Volume9
Issue number4
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Multiple Myeloma
Phosphotransferases
Neoplasms
Mutation
Acute Myeloid Leukemia
Genes
Ectopic Gene Expression

ASJC Scopus subject areas

  • Hematology

Cite this

@article{7ec58c65074d45d6b77871fd170d8d99,
title = "The enigma of ectopic expression of FGFR3 in multiple myeloma: A critical initiating event or just a target for mutational activation during tumor progression",
abstract = "The t(4;14)(pl 6.3;q32) translocation that occurs uniquely in a subset of multiple myeloma tumors results in ectopic expression of wild-type FGFR3 and enhanced expression of MMSET, a gene that is homologous to the MLL gene that is involved in acute myeloid leukemias. Wild-type FGFR3 appears to be weakly transforming in a hematopoietic murine model, whereas FGFR3 that contains kinase-activating mutations is strongly transforming in NIH3T3 cells and the hematopoietic model. The subsequent acquisition of FGFR3 kinase-activating mutations in some tumors with t(4;14) translocations confirms a role for FGFR3 in tumor progression. However, it remains to be proven if and how dysregulation of FGFR3 or MMSET mediates an early oncogenic process in multiplemyeloma.",
author = "Marta Chesi and Bergsagel, {Peter Leif} and Kuehl, {W. Michael}",
year = "2002",
doi = "10.1097/00062752-200207000-00005",
language = "English (US)",
volume = "9",
pages = "288--293",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - The enigma of ectopic expression of FGFR3 in multiple myeloma

T2 - A critical initiating event or just a target for mutational activation during tumor progression

AU - Chesi, Marta

AU - Bergsagel, Peter Leif

AU - Kuehl, W. Michael

PY - 2002

Y1 - 2002

N2 - The t(4;14)(pl 6.3;q32) translocation that occurs uniquely in a subset of multiple myeloma tumors results in ectopic expression of wild-type FGFR3 and enhanced expression of MMSET, a gene that is homologous to the MLL gene that is involved in acute myeloid leukemias. Wild-type FGFR3 appears to be weakly transforming in a hematopoietic murine model, whereas FGFR3 that contains kinase-activating mutations is strongly transforming in NIH3T3 cells and the hematopoietic model. The subsequent acquisition of FGFR3 kinase-activating mutations in some tumors with t(4;14) translocations confirms a role for FGFR3 in tumor progression. However, it remains to be proven if and how dysregulation of FGFR3 or MMSET mediates an early oncogenic process in multiplemyeloma.

AB - The t(4;14)(pl 6.3;q32) translocation that occurs uniquely in a subset of multiple myeloma tumors results in ectopic expression of wild-type FGFR3 and enhanced expression of MMSET, a gene that is homologous to the MLL gene that is involved in acute myeloid leukemias. Wild-type FGFR3 appears to be weakly transforming in a hematopoietic murine model, whereas FGFR3 that contains kinase-activating mutations is strongly transforming in NIH3T3 cells and the hematopoietic model. The subsequent acquisition of FGFR3 kinase-activating mutations in some tumors with t(4;14) translocations confirms a role for FGFR3 in tumor progression. However, it remains to be proven if and how dysregulation of FGFR3 or MMSET mediates an early oncogenic process in multiplemyeloma.

UR - http://www.scopus.com/inward/record.url?scp=0036014969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036014969&partnerID=8YFLogxK

U2 - 10.1097/00062752-200207000-00005

DO - 10.1097/00062752-200207000-00005

M3 - Article

C2 - 12042702

AN - SCOPUS:0036014969

VL - 9

SP - 288

EP - 293

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 4

ER -